Loading
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Latest filing published 14 Aug 2023 for Sigilon Therapeutics, Inc., €23.3M.
Filing timeline
BuySaleLILLY & Co ELI
Insider track record
Disclosed buys
2
Disclosed sells
0
Signal history
Closed purchases
Market purchases
2
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
LILLY & Co ELI: trading record in brief
This profile gathers the share dealings of LILLY & Co ELI across 2 companies, led by Sigilon Therapeutics, Inc. and Avidity Biosciences, Inc. Between 16 June 2020 and 11 August 2023, the trades on record add up to 4 filings.
Every open-market trade on record is a purchase: 2 purchases worth €27.8M, and no sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Since January 2023: 1 purchase and no sales on the market.
The record was last updated on 14 August 2023 with an open-market purchase (€23.3M) in Sigilon Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to LILLY & Co ELI
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
1,718,493 shares@ US$14.92100.0% of flowCommon StockSEC:0000899243-23-018115:0
Canonical exit: 9 Nov 2023 (T+90)
300,000 shares@ US$18.0016.0% of flowCommon StockSEC:0000059478-20-000187:1
Canonical exit: 8 Mar 2021 (T+90)
2,444,443 sharesCommon StockSEC:0000059478-20-000187:0
2,169,396 sharesCommon StockSEC:0001140361-20-013983:0
4 of 4 declarations
